Obicetrapib (TA-8995)
Hypercholesterolemia / HeFH / ASCVD
Key Facts
About NewAmsterdam Pharma Company
NewAmsterdam Pharma is a Netherlands-based, NASDAQ-listed biotech dedicated to developing obicetrapib, a novel oral CETP inhibitor for cardiovascular and metabolic diseases. The company has rapidly advanced its lead asset through a robust Phase 3 program, securing major partnerships and over $1.2 billion in funding to date. Its strategy hinges on demonstrating obicetrapib's potent LDL-lowering efficacy and cardiovascular outcomes benefit to capture a multi-billion dollar market opportunity in high-risk patient populations inadequately served by statins and PCSK9 inhibitors.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is a Netherlands-based, NASDAQ-listed biotech dedicated to developing obicetrapib, a novel oral CETP inhibitor for cardiovascular and metabolic diseases. The company has rapidly advanced its lead asset through a robust Phase 3 program, securing major partnerships and over $1.2 billion in funding to date. Its strategy hinges on demonstrating obicetrapib's potent LDL-lowering efficacy and cardiovascular outcomes benefit to capture a multi-billion dollar market opportunity in high-risk patient populations inadequately served by statins and PCSK9 inhibitors.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is a Netherlands-based, NASDAQ-listed biotech dedicated to developing obicetrapib, a novel oral CETP inhibitor for cardiovascular and metabolic diseases. The company has rapidly advanced its lead asset through a robust Phase 3 program, securing major partnerships and over $1.2 billion in funding to date. Its strategy hinges on demonstrating obicetrapib's potent LDL-lowering efficacy and cardiovascular outcomes benefit to capture a multi-billion dollar market opportunity in high-risk patient populations inadequately served by statins and PCSK9 inhibitors.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is a Netherlands-based, NASDAQ-listed biotech dedicated to developing obicetrapib, a novel oral CETP inhibitor for cardiovascular and metabolic diseases. The company has rapidly advanced its lead asset through a robust Phase 3 program, securing major partnerships and over $1.2 billion in funding to date. Its strategy hinges on demonstrating obicetrapib's potent LDL-lowering efficacy and cardiovascular outcomes benefit to capture a multi-billion dollar market opportunity in high-risk patient populations inadequately served by statins and PCSK9 inhibitors.
View full company profile